Adagene to present on interim Phase 1b/2 results for antibody colorectal cancer trial

  Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target -

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

https://www.globenewswire.com/news-release/2024/01/04/2803770/0/en/Adagene-To-Present-Interim-Results-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-MSS-CRC-at-ASCO-GI-Symposium.html